Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:

$$(R_3)_p$$

$$(R_1)_m$$

$$R_2$$

$$(1)$$

wherein:

R₁ is hydrogen, hydroxy, fluoro, chloro, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy, C₁₋₆alkoxy or haloC₁₋₆alkoxy;

m is 0 when is a double bond and m is 1 when is a single bond;

 $R_2 \text{ is hydrogen, halogen, cyano, nitro, } C_{1-6}\text{alkyl, } C_{3-7}\text{cycloalkyl, } C_{3-7}\text{cycloalkyloxy, halo} C_{1-6}\text{alkyl, } C_{1-6}\text{alkoxy, halo} C_{1-6}\text{alkoxy, } C_{1-6}\text{alkylthio, amino, mono-ormal cycloses} C_{1-6}\text{alkyl, } C_{1-6}\text{alkoxy, halo} C_{1-6}$

- di-C₁-6alkylamino or an N-linked 4 to 7 membered heterocyclic group;
 - X is -(CH₂-CH₂)-, -(CH=CH)-, -(CH₂)₃-, -C(CH₃)₂-, -(CH=CH-CH₂)-, -(CH₂-CH=CH)- or a group -(CHR₅)- wherein R₅ is hydrogen, halogen, hydroxy, cyano, nitro, C₁₋₆alkyl, C₃-rcycloalkyloxy, haloC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy or C₁₋₆alkylthio;
- R3 is halogen, cyano, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy, C₁₋₆alkoxy, C₁₋₆alkylthio, hydroxy, amino, mono- or di-C₁-6alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, aryl, arylC₁-6alkyl, arylC₁-6alkyloxy, arylC₁-6alkylthio or COOR₆, CONR₇R₈ or COR₉ wherein R₆, R₇, R₈ and R₉ are independently hydrogen or C₁₋₆alkyl;
- 20 p is 0, 1 or 2 or 3;

R₄ is hydrogen, halogen, hydroxy, cyano, nitro, C₁₋₆alkyl, C₁₋₆alkanoyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy, haloC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkylthio, amino, mono- or di-C₁₋₆alkylamino or an N-linked 4 to 7 membered heterocyclic group;

Y is oxygen, sulfur, -CH₂- or NR₁₀ wherein R₁₀ is hydrogen or C₁₋₆alkyl;

- D is a single bond, -CH₂-, -(CH₂)₂- or -CH=CH-; and Z is an optionally substituted C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, an optionally substituted N-linked 4 to 7 membered heterocyclic group, or Z is -NR₁₁R₁₂ where R₁₁ and R₁₂ are independently hydrogen or C₁₋₆alkyl.
- 30 2. A compound as claimed in claim 1, wherein X is -CH2-.
 - 3. A compound as claimed in claim 1 or claim 2, wherein when $\frac{1}{2}$ is a single bond, R₁ is hydrogen, hydroxy or C₁₋₆alkoxy.
- 35 4. A compound as claimed in claim 1 having the following formula (la):

$$(R_3)_p$$

$$(Ia)$$

wherein R₃, p, R₄, Y, D, Z, ====== are as defined in claim 1 and X₁ is -CH₂- or -HC(OH)-.

- 5. A compound as claimed in any of claims 1-4, wherein p is 1 or 2 and R₃ is/are halogen, particularly chloro or fluoro, attached at the 3 or the 3,4-positions of the phenyl ring.
- 6. A compound as claimed in any of claims 1-5, wherein R₄ is C₁₋₆alkoxy (particularly methoxy), OCF₃, halogen or cyano.
 - 7. A compound as claimed in any of claims 1-6, wherein D is -CH₂-.
 - 8. A compound as claimed in any of claims 1-7, wherein Y is oxygen.

9. A compound as claimed in any of claims 1-8, wherein Z is an optionally substituted N-linked 4 to 7 membered heterocyclic group.

١...

10. A compound as claimed in claim 9, wherein Z is piperidyl.

11. A compound as claimed in claim 1 which is:

15

20

30

- 3-(3,4-Dichloro-phenyl)-3-hydroxy-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyll-pyrrolidin-2-one
- 3-(3,4-Dichloro-phenyl)-3-hydroxy-1-[4-methoxy-3-(2-morpholin-4-yl-ethoxy)-phenyl]-pyrrolidin-2-one
 3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-
 - 1-[4-Chloro-3-(2-piperidin-1-yl-ethoxy)-phenyl]-3-(3,4-dichloro-phenyl)-pyrrolidin-2-
- 1-[4-Chloro-3-(2-piperidin-1-yl-ethoxy)-phenyl]-3-(3,4-dichloro-phenyl)-3-hydroxy-pyrrolidin-2-one
 - 3-(3,4-Dichloro-phenyl)-1-(4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl)-pyrrolidin-2-one
- 35 3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrol-2-one
 - 3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(2-morpholin-4-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrol-2-one
- 1-[4-Chloro-3-(2-piperidin-1-yl-ethoxy)-phenyl]-3-(3,4-dichloro-phenyl)-1,5-dihydro-pyrrol-2-one

	3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrol-2-one
	3-(3-Fluoro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro pyrrol-2-one
5	3-(3,4-Dichloro-phenyl)-1-(-3-[2-(4,4-difluoro-piperidin-1-yl)-ethoxy]-4-methoxy-phenyl)-1,5-dihydro-pyrrol-2-one
	3-(3-Fluoro-phenyl)-5-hydroxy-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one
10	1-[4-Chloro-3-(2-piperidin-1-yl-ethoxy)-phenyl]-3-(3,4-dichloro-phenyl)-5-hydroxy pyrrolidin-2-one
10	3-(3,4-Dichloro-phenyl)-1-(-3-[2-(4,4-difluoro-piperidin-1-yl)-ethoxy]-4-methoxy-phenyl)-5-hydroxy-pyrrolidin-2-one
	3-(3-Fluoro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one
15	3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-
	pyrrolidin-2-one 3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-3-methy pyrrolidin-2-one hydrochloride salt
20	3-(3-Chloro-phenyl)-1-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl}-1,5-dihydro-pyrrol-2-one hydrochloride salt
	3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-3,4-dihydro-1H-pyridin-2-one
	3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-piperidir
25	2-one 3-(3,4-Dichloro-phenyl)-1-(4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-
	phenyl)-3,4-dihydro-pyrrol-2-one 3-(3,4-Dichloro-phenyl)-1-(4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-
20	phenyl)-4-methyl-1,5-dihydro-pyrrol-2-one 3-(4-Chloro-phenyl)-1-(4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl)-
30	3,4-dihydro-pyrrol-2-one 3-(4-Chloro-phenyl)-1-(4-methoxy-3-[2-piperidin-1-yl)-ethoxy]-phenyl)-3,4-dihydro
	pyrrol-2-one 3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(piperidin-3-ylmethoxy)-phenyl]-pyrrolidin
35	one 3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(1-methyl-piperidin-3-ylmethoxy)-phenyl]-
	pyrrolidin-one N-{4-[3-(3,4-dichlorophenyl)-2-oxo-2,5-dihydro-1 <i>H</i> -pyrrol-1-y[]-2-[2-(1-
	piperidinyl)ethoxy]phenyl}acetamide
40	N-{4-[3-(3,4-dichlorophenyl)-2-oxo-pyrrolidin-1-yl]-2-[2-(1-piperidinyl)ethoxy]phenyl}acetamide
	3-(3,4-Dichloro-phenyl)-1-{4-methoxy-3-[2-(4-methyl)-piperidin-1-yl-ethoxy]-phenyl}-3-methyl-pyrrolidin-2-one
	3-(3-Chloro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one
45	3-(3-Trifluoromethyl-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one
	3-(3-Trifluoromethyl-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-
50	dihydro-pyrrol-2-one 3-(3-Chloro-phenyl)-5-methoxy-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-
50	pyrrolidin-2-one 3-(3-Chloro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro- pyrrol-2-one

3-(4-Fluoro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrol-2-one

3-(4-Fluoro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one

5 1-{4-Methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl}-3-(4-methyl-phenyl)-1,5-dihydro-pyrrol-2-one

1-{4-Methoxy-3-[2-(piperidin-1-yl)-ethoxy]-phenyl}-3-(4-methyl-phenyl)-1,5-dihydropyrrol-2-one

3-(4-Bromo-phenyl)-1-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl}-

10 1,5-dihydro-pyrrol-2-one

1-{4-Methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl}-3-(4-trifluoromethyl-phenyl)-1,5-dihydro-pyrrol-2-one

3-(2-Chloro-phenyl)-1-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl}-1,5-dihydro-pyrrol-2-one

3-(3,4-Dichloro-phenyl)-3-hydroxy-1-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl}-pyrrolidin-2-one

3-(3,4-Dichloro-phenyl)-3-fluoro-1-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl}-ethoxy]-phenyl}-pyrrolidin-2-one

3-(3,4-Dichloro-phenyl)-1-{4-methoxy-3-[(1-methyl-pyrrolidin-2-yl)-methoxy]-phenyl}-pyrrolidin-2-one

3-(3,4-Dichloro-phenyl)-1-(4-methoxy-3-[(1-methyl-pyrrolidin-2-yl)-methoxy]-phenyl]-3,4-dihydro-pyrrol-2-one

or a pharmaceutically acceptable salt thereof.

- 25 12. A process for the preparation of a compound as defined in any of claims 1-11, which process comprises:
 - (a) reacting a compound of formula (II):

$$(R_3)_p$$

$$(R_1)_m$$

$$R_2$$
(II)

30

15

20

wherein R_1 , R_2 , R_3 , R_4 , m, p, X, \longrightarrow , Y and D are as defined for formula (I), and L is a leaving group, with a compound of formula (III):

35

(III)

wherein Z is as defined for formula (I); or

(b) cyclising a compound of formula (IV):

$$(R_3)_p$$

$$(R_1)_m$$

$$G$$

$$(IV)$$

wherein R_1 , R_2 , m, R_3 , p, R_4 , Y, D, Z and are as defined for formula (I) and G is a group -X=CH₂, wherein X is as defined for formula (I), dehydrogenated as required;

optionally followed by:

· removing any protecting groups; and/or

- converting a compound of formula (I) into another compound of formula (I); and/or
- forming a pharmaceutically acceptable salt.

15

10

- 13. A pharmaceutical composition comprising a compound as defined in any of claims1-14 and a pharmaceutically acceptable carrier or excipient.
- A process for preparing a pharmaceutical composition as defined in claim 13, the
 process comprising mixing a compound a compound as defined in any of claims 1-14 and a pharmaceutically acceptable carrier or excipient.
 - 15. A compound as defined in any of claims 1-11 for use as a therapeutic substance.
- 25 16. A compound as defined in any of claims 1-11 for use in the treatment of a CNS disorder.
 - 17. A compound as defined in any of claims 1-11 for use in the treatment of depression or anxiety.

30

18. A method of treatment of a CNS disorder in a mammal including a human, which comprises administering to the sufferer a therapeutically safe and effective amount of a compound as defined in any of claims 1-11.

19. A method of treatment of depression andor anxiety in a mammal including a human, which comprises administering to the sufferer a therapeutically safe and effective amount of a compound as defined in any of claims 1-11.

5 20. Use of a compound as defined in any of claims 1-11 in the manufacture of a medicament for use in the treatment of a CNS disorder.

10

21. The use of a compound as defined in any of claims 1-11 in the manufacture of a medicament for use in the treatment of depression or anxiety.